What is claimed is:

1. A compound of Formula (A1):

$$Q\text{-}L^1\text{-}E \qquad (A1)$$

or a pharmaceutically acceptable salt thereof, wherein:

Q is a moiety represented by Formula I:



I

wherein:

W is CR^W or N;

X is CR^X or N;

Y is CR^Y or N;

Z is CR^Z or N;

wherein no more than two of W, X, Y, and Z are simultaneously N;

Ring A is monocyclic or polycyclic C_{3-14} cycloalkyl or Ring A is monocyclic or polycyclic 4-18 membered heterocycloalkyl, wherein Ring A is optionally substituted by 1, 2, 3, or 4 R^A, and Ring A is attached to the $-(L)_m-$ moiety of Formula I through a non-aromatic ring when Ring A is polycyclic;

L is $-(CR^5R^6)_t-$, $-(CR^5R^6)_p-O-(CR^5R^6)_q-$, $-(CR^5R^6)_p-S-(CR^5R^6)_q-$, $-(CR^5R^6)_p-NR^3-(CR^5R^6)_q-$, $-(CR^5R^6)_p-CO-(CR^5R^6)_q-$, $-(CR^5R^6)_r-C(O)O-(CR^5R^6)_s-$, $-(CR^5R^6)_r-CONR^3-(CR^5R^6)_s-$, $-(CR^5R^6)_p-SO-(CR^5R^6)_q-$, $-(CR^5R^6)_p-SO_2-(CR^5R^6)_q-$, $-(CR^5R^6)_r-SONR^3-(CR^5R^6)_s-$, or $-NR^3CONR^4-$;

R^1 and R^2 are each, independently, selected from H and methyl;

R^3 and R^4 are each, independently, selected from H and C_{1-4} alkyl;

R^5 and R^6 are each, independently, selected from H, halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, and C_{2-8} dialkylamino;

each R^A is independently selected from halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, 4-10 membered heterocycloalkyl-C_{1-4} alkyl, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}C(O)NR^{c1}R^{d1}$, $C(=NR^{e1})R^{b1}$, $C(=NR^{e1})NR^{c1}R^{d1}$, $NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}$, $NR^{c1}S(O)R^{b1}$, $NR^{c1}S(O)_2R^{b1}$, $NR^{c1}S(O)_2NR^{c1}R^{d1}$, $S(O)R^{b1}$, $S(O)NR^{c1}R^{d1}$, $S(O)_2R^{b1}$, and $S(O)_2NR^{c1}R^{d1}$; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl of R^A are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^1, Cy^1-C_{1-4} alkyl, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $C(=NR^{e1})NR^{c1}R^{d1}$, $NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}C(O)NR^{c1}R^{d1}$, $NR^{c1}S(O)R^{b1}$, $NR^{c1}S(O)_2R^{b1}$, $NR^{c1}S(O)_2NR^{c1}R^{d1}$, $S(O)R^{b1}$, $S(O)NR^{c1}R^{d1}$, $S(O)_2R^{b1}$, and $S(O)_2NR^{c1}R^{d1}$;

R^W, R^X, R^Y, and R^Z are each, independently, selected from H, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, 4-10 membered heterocycloalkyl-C_{1-4} alkyl, CN, NO_2, OR^{a2}, SR^{a2}, $C(O)R^{b2}$, $C(O)NR^{c2}R^{d2}$, $C(O)OR^{a2}$, $OC(O)R^{b2}$, $OC(O)NR^{c2}R^{d2}$, $NR^{c2}R^{d2}$, $NR^{c2}C(O)R^{b2}$, $NR^{c2}C(O)OR^{a2}$, $NR^{c2}C(O)NR^{c2}R^{d2}$, $C(=NR^{e2})R^{b2}$, $C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}S(O)R^{b2}$, $NR^{c2}S(O)_2R^{b2}$, $NR^{c2}S(O)_2NR^{c2}R^{d2}$, $S(O)R^{b2}$, $S(O)NR^{c2}R^{d2}$, $S(O)_2R^{b2}$, and $S(O)_2NR^{c2}R^{d2}$; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl of R^W, R^X, R^Y, or R^Z are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^2, Cy^2-C_{1-4} alkyl, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, CN, NO_2, OR^{a2}, SR^{a2}, $C(O)R^{b2}$, $C(O)NR^{c2}R^{d2}$, $C(O)OR^{a2}$, $OC(O)R^{b2}$, $OC(O)NR^{c2}R^{d2}$, $C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}R^{d2}$, $NR^{c2}C(O)R^{b2}$, $NR^{c2}C(O)OR^{a2}$, $NR^{c2}C(O)NR^{c2}R^{d2}$, $NR^{c2}S(O)R^{b2}$, $NR^{c2}S(O)_2R^{b2}$, $NR^{c2}S(O)_2NR^{c2}R^{d2}$, $S(O)R^{b2}$, $S(O)NR^{c2}R^{d2}$, $S(O)_2R^{b2}$, and $S(O)_2NR^{c2}R^{d2}$;

wherein when W is CR^W, X is CR^X, Y is CR^Y, and Z is CR^Z, then at least one of R^W, R^X, R^Y, and R^Z is other than H;

each Cy^1 is independently selected from C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4

substituents independently selected from halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, 4-10 membered heterocycloalkyl-C_{1-4} alkyl, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $C(=NR^{e1})NR^{c1}R^{d1}$, $NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}C(O)NR^{c1}R^{d1}$, $NR^{c1}S(O)R^{b1}$, $NR^{c1}S(O)_2R^{b1}$, $NR^{c1}S(O)_2NR^{c1}R^{d1}$, $S(O)R^{b1}$, $S(O)NR^{c1}R^{d1}$, $S(O)_2R^{b1}$, and $S(O)_2NR^{c1}R^{d1}$;

each Cy^2 is independently selected from C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, 4-10 membered heterocycloalkyl-C_{1-4} alkyl, CN, NO_2, OR^{a2}, SR^{a2}, $C(O)R^{b2}$, $C(O)NR^{c2}R^{d2}$, $C(O)OR^{a2}$, $OC(O)R^{b2}$, $OC(O)NR^{c2}R^{d2}$, $C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}R^{d2}$, $NR^{c2}C(O)R^{b2}$, $NR^{c2}C(O)OR^{a2}$, $NR^{c2}C(O)NR^{c2}R^{d2}$, $NR^{c2}S(O)R^{b2}$, $NR^{c2}S(O)_2R^{b2}$, $NR^{c2}S(O)_2NR^{c2}R^{d2}$, $S(O)R^{b2}$, $S(O)NR^{c2}R^{d2}$, $S(O)_2R^{b2}$, and $S(O)_2NR^{c2}R^{d2}$;

each R^{a1}, R^{b1}, R^{c1}, R^{d1}, R^{a2}, R^{b2}, R^{c2}, and R^{d2} is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl of R^{a1}, R^{b1}, R^{c1}, R^{d1}, R^{a2}, R^{b2}, R^{c2}, or R^{d2} is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^3, Cy^3-C_{1-4} alkyl, halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, CN, OR^{a3}, SR^{a3}, $C(O)R^{b3}$, $C(O)NR^{c3}R^{d3}$, $C(O)OR^{a3}$, $OC(O)R^{b3}$, $OC(O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(O)R^{b3}$, $NR^{c3}C(O)NR^{c3}R^{d3}$, $NR^{c3}C(O)OR^{a3}$, $C(=NR^{e3})NR^{c3}R^{d3}$, $NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$, $S(O)R^{b3}$, $S(O)NR^{c3}R^{d3}$, $S(O)_2R^{b3}$, $NR^{c3}S(O)_2R^{b3}$, $NR^{c3}S(O)_2NR^{c3}R^{d3}$, and $S(O)_2NR^{c3}R^{d3}$;

each Cy^3 is C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, CN, OR^{a3}, SR^{a3}, $C(O)R^{b3}$, $C(O)NR^{c3}R^{d3}$, $C(O)OR^{a3}$, $OC(O)R^{b3}$, $OC(O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(O)R^{b3}$, $NR^{c3}C(O)NR^{c3}R^{d3}$, $NR^{c3}C(O)OR^{a3}$, $C(=NR^{e3})NR^{c3}R^{d3}$,

$NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$, $S(O)R^{b3}$, $S(O)NR^{c3}R^{d3}$, $S(O)_2R^{b3}$, $NR^{c3}S(O)_2R^{b3}$, $NR^{c3}S(O)_2NR^{c3}R^{d3}$, and $S(O)_2NR^{c3}R^{d3}$;

R^{a3}, R^{b3}, R^{c3}, and R^{d3} are independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, and C_{1-6} haloalkoxy;

or R^{c1} and R^{d1} together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, CN, OR^{a3}, SR^{a3}, $C(O)R^{b3}$, $C(O)NR^{c3}R^{d3}$, $C(O)OR^{a3}$, $OC(O)R^{b3}$, $OC(O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(O)R^{b3}$, $NR^{c3}C(O)NR^{c3}R^{d3}$, $NR^{c3}C(O)OR^{a3}$, $C(=NR^{e3})NR^{c3}R^{d3}$, $NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$, $S(O)R^{b3}$, $S(O)NR^{c3}R^{d3}$, $S(O)_2R^{b3}$, $NR^{c3}S(O)_2R^{b3}$, $NR^{c3}S(O)_2NR^{c3}R^{d3}$, and $S(O)_2NR^{c3}R^{d3}$;

or R^{c2} and R^{d2} together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, CN, OR^{a3}, SR^{a3}, $C(O)R^{b3}$, $C(O)NR^{c3}R^{d3}$, $C(O)OR^{a3}$, $OC(O)R^{b3}$, $OC(O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(O)R^{b3}$, $NR^{c3}C(O)NR^{c3}R^{d3}$, $NR^{c3}C(O)OR^{a3}$, $C(=NR^{e3})NR^{c3}R^{d3}$, $NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$, $S(O)R^{b3}$, $S(O)NR^{c3}R^{d3}$, $S(O)_2R^{b3}$, $NR^{c3}S(O)_2R^{b3}$, $NR^{c3}S(O)_2NR^{c3}R^{d3}$, and $S(O)_2NR^{c3}R^{d3}$;

each R^{e1}, R^{e2}, and R^{e3} is independently selected from H, C_{1-4} alkyl, and CN;

m is 0 or 1,

n is 0, 1, or 2;

p is 0, 1, or 2;

q is 0, 1, or 2, wherein p+q is 0, 1, or 2;

r is 0 or 1;

s is 0 or 1, where r+s is 0 or 1; and

t is 1, 2, or 3;

L^1 is a linker, which is covalently linked to moiety Q and to moiety E;

E is an E3 ubiquitin ligase binding moiety, which binds to the E3 ubiquitin ligase; and

wherein the wavy lines represent the points of attachment to group L^1;

wherein any aforementioned heteroaryl or heterocycloalkyl group comprises 1, 2, 3, or 4 ring-forming heteroatoms independently selected from O, N, and S;

wherein one or more ring-forming C or N atoms of any aforementioned heterocycloalkyl group is optionally substituted by an oxo (=O) group; and

wherein one or more ring-forming S atoms of any aforementioned heterocycloalkyl group is optionally substituted by one or two oxo (=O) groups.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein linker L^1 is a chain of 1 to 40, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, or 1 to 5 chain atoms, which is optionally substituted with 1-3 R^q substituents, and wherein one or more chain carbon atoms of L^1 can be oxidized to form a carbonyl (C=O), and wherein one or more N and S chain atoms can each be optionally oxidized to form an amine oxide, sulfoxide or sulfonyl group; and

each R^q is independently selected from OH, CN, -COOH, NH_2, halo, C_{1-6} haloalkyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C_{3-6} cycloalkyl, NH(C_{1-6} alkyl) and N(C_{1-6} alkyl)$_2$, wherein the C_{1-6} alkyl, phenyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R^q are each optionally substituted with halo, OH, CN, -COOH, NH_2, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, phenyl, C_{3-10} cycloalkyl, 5- or 6-membered heteroaryl or 4-6 membered heterocycloalkyl.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein linker L^1 has the structure:



wherein each G is independently selected from –C(O)-, -NR^GC(O)-, -NR^G-, -O-, -S-, -C(O)O-, -OC(O)NR^G-, -NR^GC(O)NR^G-, -S(O_2)-, or -S(O)NR^G-;

each R^G is independently selected from H, methyl, and ethyl;

a is 0 or 1;

b is 0 or 1; and

c is 0 or 1, wherein the wavy lines represent points of attachment to moieties Q and E.

4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein a is 1, b is 1, and c is 1.

5. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein a is 0, b is 1, and c is 0.

6. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein a is 1, b is 1, and c is 0.

7. The compound of any one of claims 3-6, or a pharmaceutically acceptable salt thereof, wherein each G is independently selected from -C(O)- and -NR^GC(O)-.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein linker L^1 is selected from:


,

,

,

, and

wherein the wavy lines represent points of attachment to moieties Q and E.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein E is a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety.

10. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein E is a moiety having a structure selected from:


,

,


,


,


,


,


,


,


,


,


,


, and


;

wherein the wavy lines represent the point of attachment to group L^1.

11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein E has the following structure:


,

wherein the wavy line represents the point of attachment to L^1.

12. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein E has the following structure:


,

wherein the wavy line represents the point of attachment to L^1.

13. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein E has the following structure:


,

wherein the wavy line represents the point of attachment to L^1.

14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein W is CR^W; X is CR^X; Y is CR^Y; and Z is CR^Z.

15. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof wherein W is N; X is CR^X; Y is CR^Y; and Z is CR^Z.

16. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein W is CR^W; X is N; Y is CR^Y; and Z is CR^Z.

17. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein W is CR^W; X is CR^X; Y is N; and Z is CR^Z.

18. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein W is CR^W; X is CR^X; Y is CR^Y; and Z is N.

19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein Ring A is monocyclic or polycyclic C_{3-14} cycloalkyl optionally substituted by 1, 2, 3, or 4 R^A, wherein Ring A is attached to the $-(L)_m-$ moiety of Formula I through a non-aromatic ring when Ring A is polycyclic.

20. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein Ring A is cyclohexyl optionally substituted by 1, 2, 3, or 4 R^A.

21. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein Ring A is monocyclic or polycyclic 4-18 membered heterocycloalkyl optionally substituted by 1, 2, 3, or 4 R^A, and wherein Ring A is attached to the $-(L)_m-$ moiety of Formula I through a non-aromatic ring when Ring A is polycyclic.

22. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein Ring A is piperidinyl optionally substituted by 1, 2, 3, or 4 R^A.

23. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein Ring A is piperidin-4-yl optionally substituted by 1, 2, 3, or 4 R^A.

24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein L is $-CH_2-$.

25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein m is 0.

26. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein m is 1.

27. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein n is 0.

28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are both H.

29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein each R^A is independently selected from C_{1-6} alkyl, OR^{a1}, $C(O)R^{b1}$, $NR^{c1}R^{d1}$, and $S(O)_2R^{b1}$; wherein said C_{1-6} alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^1, Cy^1-C_{1-4} alkyl, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $C(=NR^{e1})NR^{c1}R^{d1}$, $NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}C(O)NR^{c1}R^{d1}$, $NR^{c1}S(O)R^{b1}$, $NR^{c1}S(O)_2R^{b1}$, $NR^{c1}S(O)_2NR^{c1}R^{d1}$, $S(O)R^{b1}$, $S(O)NR^{c1}R^{d1}$, $S(O)_2R^{b1}$, and $S(O)_2NR^{c1}R^{d1}$.

30. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein each R^A is independently selected from halo, C_{1-6} haloalkyl, OR^{a1}, $C(O)NR^{c1}R^{d1}$, and $C(O)OR^{a1}$.

31. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein each R^W, R^X, R^Y, and R^Z is independently selected from H, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, CN, OR^{a2}, $C(O)NR^{c2}R^{d2}$, $NR^{c2}R^{d2}$, and $NR^{c2}C(O)R^{b2}$; wherein said C_{1-6} alkyl, C_{1-6} haloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, and C_{6-10} aryl-C_{1-4} alkyl of R^W, R^X, R^Y, and R^Z are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^2, Cy^2-C_{1-4} alkyl, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, CN, NO_2, OR^{a2}, SR^{a2}, $C(O)R^{b2}$, $C(O)NR^{c2}R^{d2}$, $C(O)OR^{a2}$, $OC(O)R^{b2}$, $OC(O)NR^{c2}R^{d2}$, $C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}R^{d2}$, $NR^{c2}C(O)R^{b2}$, $NR^{c2}C(O)OR^{a2}$, $NR^{c2}C(O)NR^{c2}R^{d2}$, $NR^{c2}S(O)R^{b2}$, $NR^{c2}S(O)_2R^{b2}$, $NR^{c2}S(O)_2NR^{c2}R^{d2}$, $S(O)R^{b2}$, $S(O)NR^{c2}R^{d2}$, $S(O)_2R^{b2}$, and $S(O)_2NR^{c2}R^{d2}$.

32. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein W is CR^W and R^W is other than H.

33. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein R^W is halo.

34. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein R^W is F.

35. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt thereof, wherein X is CR^X and R^X is H.

36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein Y is CR^Y and R^Y is other than H.

37. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein Y is CR^Y and R^Y is independently selected from C_{1-6} alkyl, OR^{a2}, $NR^{c2}R^{d2}$, $NR^{c2}C(O)R^{b2}$, $NR^{c2}C(O)OR^{a2}$, $NR^{c2}C(O)NR^{c2}R^{d2}$, $C(=NR^{e2})R^{b2}$, $C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}S(O)R^{b2}$, $NR^{c2}S(O)_2R^{b2}$, and $NR^{c2}S(O)_2NR^{c2}R^{d2}$.

38. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein Y is CR^Y and R^Y is independently selected from C_{1-6} alkyl, C_{3-7} cycloalkyl-

C_{1-4} alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, halo, CN, OR^{a2}, SR^{a2}, $C(O)NR^{c2}R^{d2}$, $NR^{c2}R^{d2}$, $NR^{c2}C(O)R^{b2}$, $NR^{c2}C(O)OR^{a2}$, $NR^{c2}C(O)NR^{c2}R^{d2}$, $C(=NR^{e2})R^{b2}$, $C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}S(O)R^{b2}$, $NR^{c2}S(O)_2R^{b2}$, and $NR^{c2}S(O)_2NR^{c2}R^{d2}$, wherein said C_{1-6} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of R^Y are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C_{1-6} alkyl, C_{1-6} haloalkyl, CN, NO_2, OR^{a2}, $NR^{c2}R^{d2}$, and $S(O)_2R^{b2}$.

39. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein Y is CR^Y and R^Y is independently selected from $NR^{c2}R^{d2}$, $NR^{c2}C(O)R^{b2}$, $NR^{c2}C(O)OR^{a2}$, $NR^{c2}C(O)NR^{c2}R^{d2}$, $C(=NR^{e2})R^{b2}$, $C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}$, $NR^{c2}S(O)R^{b2}$, $NR^{c2}S(O)_2R^{b2}$, and $NR^{c2}S(O)_2NR^{c2}R^{d2}$.

40. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein Y is CR^Y and R^Y is independently selected from C_{1-6} alkyl and OR^{a2}.

41. The compound of any one of claims 1-40, or a pharmaceutically acceptable salt thereof, wherein R^{a2} is selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{1-6} haloalkyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C_{1-4} alkyl, C_{1-4} haloalkyl, halo, CN, OR^{a3}, $C(O)R^{b3}$, $C(O)OR^{a3}$ and $S(O)_2R^{b3}$.

42. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein Y is CR^Y and R^Y is independently selected from $NR^{c2}R^{d2}$ and $NR^{c2}C(O)R^{b2}$.

43. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt thereof, wherein R^{c2} and R^{d2} are each independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{1-6} haloalkyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-4} alkyl, C_{3-7} cycloalkyl-C_{1-4} alkyl, and 4-10 membered heterocycloalkyl-C_{1-4} alkyl are each

optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C_{1-4} alkyl, C_{1-4} haloalkyl, halo, CN, OR^{a3}, $C(O)R^{b3}$, $C(O)OR^{a3}$ and $S(O)_2R^{b3}$.

44. The compound of any one of claims 1-43, or a pharmaceutically acceptable salt thereof, wherein Z is CR^Z and R^Z is H.

45. The compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, wherein Q is a moiety having Formula II:



II,

wherein the wavy lines represent the point of attachment to group L^1.

46. The compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, wherein Q is a moiety having Formula IIIA, IIIB, IIIC, IIID, or IIIE:



IIIA



IIIB





IIIC IIID



IIIE,

wherein the wavy lines represent the point of attachment to group L^1.

47. The compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, wherein Q is a moiety having Formula IVA or IVB:





IVA IVB,

wherein the wavy lines represent the point of attachment to group L^1.

48. The compound of any one of claims 1-44, having Formula (A3):



(A3),

or a pharmaceutically acceptable salt thereof.

49. The compound of any one of claims 1-44, having Formula (A4):



(A4),

or a pharmaceutically acceptable salt thereof.

50. The compound of any one of claims 1-44, having Formula (A5):



(A5),

or a pharmaceutically acceptable salt thereof.

51. The compound of any one of claims 1-44, having Formula (A6):



(A6),

or a pharmaceutically acceptable salt thereof.

52. The compound of claim 1, wherein the compound is selected from the following:



,



,



, and



; or a pharmaceutically acceptable salt of any of the aforementioned.

53. A pharmaceutical composition comprising a compound of any one of claims 1-52, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

54. The use of a compound of any one of claims 1-52, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the thereapeutic treatment of a disease affected by degradation of PARP14.

55. The use of a compound of any one of claims 1-52, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the therapeutic treatment of cancer.

56. The method of claim 55 wherein said cancer is multiple myeloma, DLBCL, hepatocellular carcinoma, bladder cancer, esophageal cancer, head and neck cancer, kidney cancer, prostate cancer, rectal cancer, stomach cancer, thyroid cancer, uterine cancer, breast cancer, glioma, follicular lymphoma, pancreatic cancer, lung cancer, colon cancer, or melanoma.

57. The use of a compound of any one of claims 1-52, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the therapeutic treatment of an inflammatory disease.

58. The use of a compound of any one of claims 1-52, or a pharmaceutically acceptable salt thereof, for the manufactur of a medicament for therapeutic treatment of a disease affected by decreased IL-10 in living cells.